Annual Report 2018
Oslo, Norway, April 9, 2019 – The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2018 and the report is attached. The Annual Report 2018 is also available on the company’s website www.pcibiotech.com. For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Per Walday, CEO, pw@pcibiotech.no, […]
Final confirmation of successful safety read-out in the Phase I Extension study
Oslo (Norway), 8 April 2019 – PCI Biotech (OSE: PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced final confirmation of successful safety read-out for the Phase I Extension study in inoperable bile duct cancer patients which currently are left without effective local treatment options. The appointed […]
Resignation of Chief Business Development Officer
Oslo (Norway), 28 February 2019 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that its Chief Business Development Officer (CBDO), Gaël L’Hévéder has resigned and will leave PCI Biotech as per end of March 2019 to pursue other career opportunities. “We regret Gaël’s departure but respect his decision,” says Per Walday, […]